Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Rona-Thera-Phase-1

More Like This

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity

PR Newswire associated0

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

PR Newswire associated0

Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions